J.D. Finley is recorded as CEO at Palisade Bio, Inc. (PALI) since October 11, 2022, CFO at Palisade Bio, Inc. (PALI) since April 27, 2021 and Board Member at Palisade Bio, Inc. (PALI) since January 1, 2021. The newest filing on record that lists J.D. Finley as CEO and Board Member at Palisade Bio, Inc. (PALI) is dated May 22, 2024. The newest filing on record that lists J.D. Finley as CFO at Palisade Bio, Inc. (PALI) is dated April 21, 2022. Palisade Bio, Inc. reported in an 8-K filed February 8, 2023 that J.D. Finley was appointed Class III member of the Board, effective February 2, 2023. Palisade Bio, Inc. reported in an 8-K filed October 14, 2022 that J.D. Finley was appointed Chief Executive Officer (principal executive officer), on an interim basis, effective October 11, 2022. The proxy statement of Palisade Bio, Inc. reports total compensation of $813,000 for J.D. Finley in fiscal 2024, including a base salary of $542,000. Disclosed compensation is on record for 5 fiscal years. J.D. Finley has spoken on 3 investor events across 1 company, most recently for Palisade Bio, Inc. on September 14, 2026. Palisade Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Palisade Bio, Inc. includes Dane R. Saglio (CFO), Matthew W. Kalnik, Ph.D. (COO), Robert McRae (COO) and 7 others.
“On February 2, 2023, the Board appointed J.D. Finley to the Board.”
Palisade Bio, Inc. Form 8-K, filed February 8, 2023
· Read the filing
“As of the Effective Date, J.D. Finley, the Company's current Chief Financial Officer, was appointed by the Board to serve as the Company's Chief Executive Officer (principal executive officer), on an interim basis.”
Palisade Bio, Inc. Form 8-K, filed October 14, 2022
· Read the filing
J.D. Finley on recent calls
“So the Peli-2108 is a drug that we acquired from a Canadian company, Giant Pharma, out of Montreal. That company was founded by some medicinal chemists from the Merck Frost Labs in Montreal When they closed that down in 2010, these guys took some of the science with them and developed this PD-4 prodrug formulation.”
“So I'll kind of give a little bit of background on our lead asset we're developing right now. I think that'll give you a sense of where we've come from. So we are developing a PD4 inhibitor for IBD.”
